BRAF and neoplasm: Of note, COMETT depletion significantly impairs the expression levels of different MAPK pathway effectors, including—but not limited to—the MET oncogene, also increasing tumor cells’ sensitivity to vemurafenib, a common inhibitor of mutated B-raf [173].